The U.S. Food and Drug Administration has delayed its decision on Orca Bio’s cell therapy Orca-T, a treatment designed for blood cancers like AML, ALL, and MDS. The new target date for approval is now July 6, 2026, instead of April 6.
The delay is due to the company submitting additional manufacturing and chemistry information requested by regulators. No new clinical trial data were needed, and the overall benefits and risks of the therapy have not changed.
Results from the Phase 3 Precision-T trial remain strong. Orca-T showed much better outcomes than standard stem cell transplants, with 78% of patients free from chronic graft-versus-host disease after one year, compared to 38% with conventional treatment. It also led to fewer severe infections, lower non-relapse mortality, and higher overall survival (94% vs. 83%).
Overall, the delay is related to technical review details rather than concerns about effectiveness or safety, and the therapy continues to show clear advantages in reducing transplant-related complications.